

# **Cell & Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis By Type, By Indication, By Application, By End-user, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030**

<https://marketpublishers.com/r/C0173EA3F574EN.html>

Date: June 2022

Pages: 245

Price: US\$ 4,250.00 (Single User License)

ID: C0173EA3F574EN

## **Abstracts**

Global Cell & Gene Therapy Manufacturing Services Market projected to be worth USD 20.68 billion by 2030.

According to SPER Market Research, the Cell & Gene Therapy Manufacturing Services Market estimated to reach USD 20.68 billion by 2030 with a CAGR of 11.6%. The collaboration between pharmaceutical companies and CDMOs, rising prevalence of cancer and various targeted disease, rising pharmaceutical research & development, High investments by CDMOs in advanced technology; these factors act as the fuel to the escalation of the market.

**Impact of COVID-19 on the Cell & Gene Therapy Manufacturing Services Market**  
Because of the outbreak of COVID-19, there is disruption of clinical trials due to the deferral of patient enrolment. Clinical trials such as; cardiovascular disease, respiratory disease, oncology, anti-infective, were the worst-hit in this time. This leads to the squeeze of production and research.

Scope of the report:

Market size available for years 2019-2030

Base year considered 2021

Forecast period 2022-2030

Segments covered By Product, By Region

Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East,

## Africa

Companies Covered ABL Inc., Andelyn Biosciences, Anemocyte Srl, BioCentriq, Catalent, Inc., Cell and Gene Therapy Catapult, Charles River Laboratories, Commercializing Living Therapies, ElevateBio, F. Hoffmann-La Roche Ltd., FinVector, FUJIFILM Holdings Corporation, JRS PHARMA, Lonza, Merck KGaA, NIKON CORPORATION, Oxford Biomedica plc, Porton Biopharma Limited, Resilience, RoslinCT, Takara Bio Inc., The Discovery Labs LLC, Thermo Fisher Scientific, Inc., Vibalogics, WuXi AppTec

**Driver:** rising investments in pharmaceutical Research & Development

The key drivers to the escalation of the market are; towering prevalence of cancer and other target diseases, rising investments in pharmaceutical research & development, funding in advanced technologies by CDMOs, escalating partnerships and agreements among CDMOs and pharmaceutical companies.

**Restraint:** High running costs coupled with cell & gene therapy manufacturing

The manufacturing of cell & gene therapy is costly; this might resist the expansion of market.

**Opportunity:** growing figure of cell & gene therapy clinical trials

The demand for cell & gene therapies is escalating globally, the elevated number of cell & gene therapy clinical trials; give the impetus to the top player in this market.

**Challenges:**

There is chances of superfluous outcomes and threat of mutagenesis; are the challenges to this market.

**Global Cell & Gene Therapy Manufacturing Services Market, By Type:**

Based on the Type, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cell Therapy {Allogeneic (Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, Other Allogeneic Cells, T-cells), Autologous (Hematopoietic Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, T-cells), Viral Vector (Adeno-associated Virus Vectors, Other Viral Vectors, Retroviral Vectors)}, Gene Therapy {Non-viral Vector, Oligonucleotides, Viral Vector (Retroviral Vectors, Adeno-associated Virus Vectors, Other Viral Vectors)}.

**Global Cell & Gene Therapy Manufacturing Services Market, By Indication:**

Based on the Indication, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cardiovascular Diseases, Central Nervous System Disorders, Infectious

Diseases, Oncology Diseases, Ophthalmology Diseases, Orthopaedic Diseases, Other Indications

Global Cell & Gene Therapy Manufacturing Services Market, By Application:

Based on the Application, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Clinical Manufacturing, Commercial Manufacturing.

Global Cell & Gene Therapy Manufacturing Services Market, By End User:

Based on the End-Users, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Other End Users.

Global Cell & Gene Therapy Manufacturing Services Market, By Region:

North America owns the prime share of this market; this is due to the increasing prevalence of cancer, increasing research in stem cell and cancer in this region.

## Contents

### 1. INTRODUCTION

- 1.1. Scope of the report
- 1.2. Market segment analysis

### 2. RESEARCH METHODOLOGY

- 2.1 Research data source
  - 2.1.1 Secondary data
  - 2.1.2 Primary data
  - 2.1.3 SPER's internal database
  - 2.1.4 Premium insight from KOL's
- 2.2 Market size estimation
  - 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation

### 3. EXECUTIVE SUMMARY

### 4. MARKET DYNAMICS

- 4.1. Driver, Restraint, Opportunity and Challenges analysis
  - 4.1.1 Drivers
  - 4.1.2 Restraints
  - 4.1.3 Opportunities
  - 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Cell & Gene Therapy Manufacturing Services Market

### 5. MARKET VARIABLES AND OUTLOOK

- 5.1. SWOT analysis
  - 5.1.1 Strengths
  - 5.1.2 Weaknesses
  - 5.1.3 Opportunities
  - 5.1.4 Threats
- 5.2. PESTEL analysis
  - 5.2.1 Political landscape
  - 5.2.2 Economic landscape

- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER'S five forces analysis
  - 5.3.1 Bargaining power of suppliers
  - 5.3.2 Bargaining power of Buyers
  - 5.3.3 Threat of Substitute
  - 5.3.4 Threat of new entrant
  - 5.3.5 Competitive rivalry
- 5.4. Heat map analysis

## **6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019-2030 (USD MILLION)**

- 6.1. Cell Therapy
  - 6.1.1. Allogeneic
    - 6.1.1.1. Hematopoietic Stem Cells
    - 6.1.1.2. Induced Pluripotent Stem Cells
    - 6.1.1.3. Mesenchymal Stem Cells
    - 6.1.1.4. Natural Killer Cells
    - 6.1.1.5. Other Allogeneic Cells
    - 6.1.1.6. T-cells
  - 6.1.2. Autologous
    - 6.1.2.1. Hematopoietic Stem Cells
    - 6.1.2.2. Mesenchymal Stem Cells
    - 6.1.2.3. Natural Killer Cells
    - 6.1.2.4. T-cells
  - 6.1.3. Viral Vector
    - 6.1.3.1. Adeno-associated Virus Vectors
    - 6.1.3.2. Other Viral Vectors
    - 6.1.3.3. Retroviral Vectors
- 6.2. Gene Therapy
  - 6.2.1. Non-viral Vector
  - 6.2.2. Oligonucleotides
    - 6.2.2.1. Other Non-viral Vectors
  - 6.2.3. Viral Vector
    - 6.2.3.1. Retroviral Vectors
    - 6.2.3.2. Adeno-associated Virus Vectors

#### 6.2.3.3. Other Viral Vectors

### **7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019-2030 (USD MILLION)**

- 7.1. Cardiovascular Diseases
- 7.2. Central Nervous System Disorders
- 7.3. Infectious Diseases
- 7.4. Oncology Diseases
- 7.5. Ophthalmology Diseases
- 7.6. Orthopedic Diseases
- 7.7. Other Indications

### **8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019-2030 (USD MILLION)**

- 8.1. Clinical Manufacturing
- 8.2. Commercial Manufacturing

### **9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION)**

- 9.1. Academic & Research Institutes
- 9.2. Other End Users
- 9.3. Pharmaceutical & Biotechnology Companies

### **10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019-2030 (USD MILLION)**

- 10.1. North America
  - 10.1.1. United States
  - 10.1.2. Canada
  - 10.1.3. Mexico
- 10.2. Europe
  - 10.2.1. Germany
  - 10.2.2. United Kingdom
  - 10.2.3. France
  - 10.2.4. Italy
  - 10.2.5. Spain

- 10.2.6. Rest of Europe
- 10.3. Asia-Pacific
  - 10.3.1. China
  - 10.3.2. Japan
  - 10.3.3. India
  - 10.3.4. Australia
  - 10.3.5. South Korea
  - 10.3.6. Rest of Asia-Pacific
- 10.4. South America
  - 10.4.1. Brazil
  - 10.4.2. Argentina
  - 10.4.3. Rest of South America
- 10.5. Middle East & Africa
  - 10.5.1. Kingdom of Saudi Arabia
  - 10.5.2. United Arab Emirates
  - 10.5.3. Rest of Middle East & Africa

## **11. COMPANY PROFILES**

- 11.1. ABL, Inc.
  - 11.1.1. Company details
  - 11.1.2. Financial outlook
  - 11.1.3. Product summary
  - 11.1.4. Recent developments
- 11.2. Andelyn Biosciences
  - 11.2.1. Company details
  - 11.2.2. Financial outlook
  - 11.2.3. Product summary
  - 11.2.4. Recent developments
- 11.3. Anemocyte Srl
  - 11.3.1. Company details
  - 11.3.2. Financial outlook
  - 11.3.3. Product summary
  - 11.3.4. Recent developments
- 11.4. BioCentriq
  - 11.4.1. Company details
  - 11.4.2. Financial outlook
  - 11.4.3. Product summary
  - 11.4.4. Recent developments

- 11.5. Catalent, Inc.
  - 11.5.1. Company details
  - 11.5.2. Financial outlook
  - 11.5.3. Product summary
  - 11.5.4. Recent developments
- 11.6. Cell and Gene Therapy Catapult
  - 11.6.1. Company details
  - 11.6.2. Financial outlook
  - 11.6.3. Product summary
  - 11.6.4. Recent developments
- 11.7. Charles River Laboratories
  - 11.7.1. Company details
  - 11.7.2. Financial outlook
  - 11.7.3. Product summary
  - 11.7.4. Recent developments
- 11.8. Commercializing Living Therapies
  - 11.8.1. Company details
  - 11.8.2. Financial outlook
  - 11.8.3. Product summary
  - 11.8.4. Recent developments
- 11.9. ElevateBio
  - 11.9.1. Company details
  - 11.9.2. Financial outlook
  - 11.9.3. Product summary
  - 11.9.4. Recent developments
- 11.10. F. Hoffmann-La Roche Ltd.
  - 11.10.1. Company details
  - 11.10.2. Financial outlook
  - 11.10.3. Product summary
  - 11.10.4. Recent developments
- 11.11. FinVector
  - 11.11.1. Company details
  - 11.11.2. Financial outlook
  - 11.11.3. Product summary
  - 11.11.4. Recent developments
- 11.12. FUJIFILM Holdings Corporation
  - 11.12.1. Company details
  - 11.12.2. Financial outlook
  - 11.12.3. Product summary



- 11.12.4. Recent developments
- 11.13. JRS PHARMA
  - 11.13.1. Company details
  - 11.13.2. Financial outlook
  - 11.13.3. Product summary
  - 11.13.4. Recent developments
- 11.14. Lonza
  - 11.14.1. Company details
  - 11.14.2. Financial outlook
  - 11.14.3. Product summary
  - 11.14.4. Recent developments
- 11.15. Merck KGaA
  - 11.15.1. Company details
  - 11.15.2. Financial outlook
  - 11.15.3. Product summary
  - 11.15.4. Recent developments
- 11.16. NIKON CORPORATION
  - 11.16.1. Company details
  - 11.16.2. Financial outlook
  - 11.16.3. Product summary
  - 11.16.4. Recent developments
- 11.17. Oxford Biomedica plc
  - 11.17.1 Company details
  - 11.17.2 Financial outlook
  - 11.17.3 Product summary
  - 11.17.4 Recent developments
- 11.18. Porton Biopharma Limited
  - 11.18.1. Company details
  - 11.18.2. Financial outlook
  - 11.18.3. Product summary
  - 11.18.4. Recent developments
- 11.19. Resilience
  - 11.19.1. Company details
  - 11.19.2. Financial outlook
  - 11.19.3. Product summary
  - 11.19.4. Recent developments
- 11.20. RoslinCT
  - 11.20.1. Company details
  - 11.20.2. Financial outlook

- 11.20.3. Product summary
- 11.20.4. Recent developments
- 11.21. Takara Bio Inc.
  - 11.21.1. Company details
  - 11.21.2. Financial outlook
  - 11.21.3. Product summary
  - 11.21.4. Recent developments
- 11.22. The Discovery Labs LLC
  - 11.22.1. Company details
  - 11.22.2. Financial outlook
  - 11.22.3. Product summary
  - 11.22.4. Recent developments
- 11.23. Thermo Fisher Scientific, Inc.
  - 11.23.1. Company details
  - 11.23.2. Financial outlook
  - 11.23.3. Product summary
  - 11.23.4. Recent developments
- 11.24. Vibalogics
  - 11.24.1. Company details
  - 11.24.2. Financial outlook
  - 11.24.3. Product summary
  - 11.24.4. Recent developments
- 11.25. WuXi AppTec
  - 11.25.1 Company details
  - 11.25.2 Financial outlook
  - 11.25.3 Product summary
  - 11.25.4 Recent developments

## I would like to order

Product name: Cell & Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis By Type, By Indication, By Application, By End-user, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Product link: <https://marketpublishers.com/r/C0173EA3F574EN.html>

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0173EA3F574EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970